CMS Brain Drain, Brain Gain
This article was originally published in RPM Report
A look at the key players who left CMS, and the influx of talent coming in.
You may also be interested in...
Medicare Part D and prescription drug prices come up briefly in a brief appearance by controversial CMS head Berwick before the Senate Finance Committee.
The Centers for Medicare & Medicaid Services is showing a lot more interest in ensuring broad access to low-cost generic drugs now that the agency is overseeing the implementation of Medicare Part D. As evidence of this trend, CMS considered weighing in on a court decision regarding the availability of Zocoor generics.
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.